Docket No. ORT-1527

MAY 1 4 2004 23

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Thomas P. Burris, et. al.

Serial No.: 09/990,461

Art Unit: 1624

Filed

: November 21, 2001


Examiner: Richard L. Raymond

For

: BIOLOGICALLY ACTIVE 4h-BENZO [1,4] OXAZIN-3-ONES-3-

ONES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on



Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

\[
\textstyle{\textstyle{\textstyle{100}}}\]

In accordance with \$1.97(b), since this Information

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)),

-
(other than a continued prosecution application under §1.53(d)),
within three months of the date of entry into the national stage
of the above identified application as set forth in \$1.491, or
before the mailing date of a first Office Action on the merits of
the above-identified application, or before the mailing date of a
first Office Action after the filing of a request for continued
examination under \$1.114, no additional fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with [] the
first or Second After Final Submission, therefore:
<pre>Statement in Accordance with \$1.97(e) (attached);</pre>
or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth in
§1.17(p).
☐ In accordance with \$1.97(c), this Information
Disclosure Statement is being filed after the period set forth in
§1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or an
action that otherwise closes prosecution and that it is
accompanied by one of:
<pre>Statement in Accordance with \$1.97(e) (attached);</pre>
or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth in
\$1.17(p).
-

	In accordance with \$1.97(d), this Information
	Disclosure Statement is being filed after the mailing date of
	either a Final Action under \$1.113 or a Notice of Allowance under
	\$1.311 but before the payment of the Issue Fee. Applicant(s)
	hereby petition(s) for consideration of this Information
	Disclosure Statement. Included are: Statement in Accordance with
	\$1.97(e) as set forth below and the fee of $$180.00$ as set forth in
	§1.17(p).
	Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
	Copies of references listed on the attached Form PTO- 1449 are enclosed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will endeavor
	to supply copies at the Examiner's request.
	Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).
	(The U.S. patents and each U.S. patent application publication
	listed on the attached Form PTO-1449 are not enclosed because this
	U.S. patent application was filed after June 30, 2003 or this
•	international application has entered the national stage under 35
	USC §371 after June 30, 2003 (see USPTO waiver of requirement
	under 37 CFR 1.98 (a)(2)(i).

•	$oxed{\boxtimes}$ There are no listed references which are not in the
	English language.
	The relevance of those listed references which are not
	in the English language is as follows:
	<pre>Attached are copies of search report(s) from</pre>
	corresponding patent application(s), which are listed on the
	attached Submission Under MPEP 609 D.
	Attached are the following non-published pending patent
	applications which may be deemed relevant, which are listed on the
	attached Submission Under MPEP 609 D.
•	
	Please charge any deficiency or credit any overpayment to
	Deposit Account No. 10-0750/ORT-1527/EDS. This form is submitted
	in triplicate.
	Respectfully submitted,
	Evelyn D. (Shen
	Reg. No. 39,834
	Attorney for Applicants
	Johnson & Johnson
	One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003
	(732) 524-6040
	DATED: 12 MAY 2004
	•

.

Under the report

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

COROCHOR OF INFORMATION WINCOOK GROPING	a valid Onio donio di marriconi
Application Number	09/990,461
Filing Date	November 21, 2001
First Named Inventor	Thomas P. Burris
Group Art Unit	1624
Examiner Name	Richard L. Raymond
Attorney Docket Number	ORT-1527
	1

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T ²		
Examiner's	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	1 1		
Initials*	NO.	HILLIARD, JAMESE J. et. al. "Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-			
		component systems" ANTIMICROB. AGENTS CHEMOTHER. (1999), 43(7), 1693-1699, XP002171516 the whole document, especially page 1695, fig.1			
			 		
ļ					
			 		
			 		
 					
					
			†		
			 		
			 		
			 		
			 		
 					
 	ļ		 		
 			 		
 					

Examiner	Date
Signature	Considered
0.2	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.